Summary Thirty-six consecutive patients with breast cancer and liver metastases with abnormal liver biochemistry were treated with epirubicin 25 mg m-2 i.v. weekly. No dose modification was made for abnormal liver biochemistry, but dose intensity was adjusted by delaying treatment according to myelosuppression. The UICC overall response rate according to UICC criteria was 11/36 (30%) and median response duration was 27 weeks. Liver biochemistry improved in a further seven patients. Treatment was well tolerated. Epirubicin given in this way is effective in patients with breast cancer and liver metastases. An initial deterioration in liver biochemistry may occur before there is a response to epirubicin.
Liver metastases are common in patients with advanced breast cancer. The prognosis is worse for these patients than after recurrence in either soft tissue (Fentiman et al., 1986) or bone (Coleman & Rubens, 1987) . Survival is particularly poor in patients with liver metastases and abnormal liver biochemistry (Swenerton et al., 1979; Zinser et al., 1987; S.M. O'Reilly, in preparation). The treatment of patients with liver metastases is difficult. Responses to endocrine therapy are uncommon (Australia & New Zealand Breast Cancer Trials Group, 1986) . The administration of chemotherapy may be complicated by the liver's role in both cytotoxic drug activation, as for cyclophosphamide (Bagley et al., 1973) , and metabolism, as with doxorubicin (Benjamin et al., 1974) . Moreover, although anthracyclines are the most active single agents in patients with breast cancer (Steiner et al., 1983) , toxicity can be severe in patients with impaired liver function and reduced hepatic drug clearance (Benjamin et al., 1974) .
Epirubicin (4'-epidoxorubicin) is a new anthracycline, structurally related to doxorubicin and with similar activity in patients with advanced breast cancer (Brambilla et al., 1986) . It is eliminated more rapidly than doxorubicin (Camaggi et al., 1988) and, at equimolar doses, is less toxic than doxorubicin (Brambilla et al., 1986) . We report our experience of the efficacy and toxicity of epirubicin in patients with breast cancer and liver metastases who have abnormal liver biochemistry.
Patients received a low dose of epirubicin on a weekly schedule, with the aim of giving a high dose intensity whilst minimising toxicity.
Patients and methods
Thirty-six patients with histologically proven breast cancer, progressive liver metastases and abnormal liver biochemistry were entered into this phase II study. During the first month of treatment, serum bilirubin or AST rose by at least 25% in seven of the 18 responders. Six of these seven patients had a raised serum bilirubin before chemotherapy. As chemotherapy continued liver biochemistry subsequently improved, and by 6 weeks these patients could clearly be distinguished from those with progressive disease in whom there was a steady deterioration. Figure I shows the two patterns of serial liver biochemistry we observed in patients who achieved a UICC response. Eleven patients received further chemotherapy at relapse. Six of these patients were treated again with epirubicin and two achieved a second response. Four patients were treated with a combination of cyclophosphamide, methotrexate and 5-fluoruoracil and one with cyclophosphamide alone, but none responded.
Median survival for all patients was 16 weeks (range 1-54) (Figure 2 ). There were no deaths directly related to chemotherapy but two patients died without evidence of disease progression, one from gastrointestinal haemorrhage and one with a pulmonary embolism which was confirmed at post-mortem. Twelve patients died within 6 weeks of starting chemotherapy. Ten of these 12 patients had had a 4-fold or greater elevation in initial AST which strongly predicted for early death (P = 0.025, Fisher's exact test). Survival for the biochemical responders was similar to that for UICC responders (P = 0.14, log rank test), and was significantly better than for patients with progressive disease (P = 0.03, log rank test).
All patients were evaluable for toxicity. Treatment was (Steiner et al., 1983) and is more effective at high (70 mg m2) than low (35 mg m2) doses (Carmo-Pereira et al., 1987) . However, because anthracyclines are metabolised by the liver, elimination is delayed in patients with liver dysfunction (Benjamin et al., 1984) . Unfortunately there is only a poor correlation between conventional liver biochemical tests and anthracycline metabolism (Preiss et al., 1987) and dose adjustments based on these tests are empirical (Benjamin et al., 1974) . Epirubicin is also metabolised principally by the liver (Camaggi et al., 1982) , and the manufacturers recommend dose reduction in patients with moderate or severe liver impairment as defined by raised serum bilirubin or bromsulphthalein clearance. In this study such dose modifications were not made. We adjusted dose intensity according to myelosuppression; in this way any effect of decreased epirubicin clearance due to impaired liver function led to a delay in treatment and reduction in dose intensity. Few studies have been directed specifically at breast cancer patients with liver metastases (Zinser et al., 1987; O'Reilly et al., 1989) . The majority of reports of chemotherapy in such patients have been derived from larger studies of patients with metastatic disease in a varity of sites. A review of these trials by Kemeny (1983) showed a response rate for liver metastases of between 30 and 75%. These results are not, however, directly comparable with those in the current study. Details of disturbances in liver biochemistry were not given, although abnormalities of liver biochemistry confer a poor prognosis (Swenerton et al., 1979; Zinser et al., 1987; O'Reilly et al., 1989) . Indeed, many studies have specifically excluded patients with abnormal liver biochemistry although at least a third of breast cancer patients have a 2-fold or greater elevation in AST at the time of diagnosis of liver metastases (Zinser et al., 1987; S.M. O'Reilly, in preparation (Larroquette et al., 1986) , and patients with hepatocellular carcinoma treated with mitoxantrone (Yoshida et al., 1988) . Whatever the mechanism of the initial deterioration in liver biochemistry, it is important to note that, although liver biochemistry may be a useful indicator of response to chemotherapy, it is not a reliable measure of progression during the first few weeks of treatment. Chemotherapy should be continued for at least 6 weeks before response is assessed, as an initial deterioration in liver biochemistry does not necessarily indicate disease progression.
We adjusted dose intensity of epirubicin according to the severity of myelosuppression alone, regardless of liver biochemistry, and found no difference in the number of treatment delays between patients with normal or raised bilirubin. A conventional dose reduction might have exposed some patients to suboptimal chemotherapy and others to unacceptable toxicity. Comparison with historical results from Guy's Breast Unit suggests that epirubicin given in this way is more active than either mitoxantrone (O'Reilly et al., 1989) or other chemotherapy (predominantly adriamycin at 3-weekly intervals or a combination of cyclophosphamide, methotrexate and 5-fluorouracil) in this group of patients (S.M. O'Reilly, in preparation). However, median survival in this study was only 16 weeks and, although responders gained symptomatic benefit, it remains uncertain whether chemotherapy improves survival in patients with liver metastases. Nevertheless, it seems likely that in this study epirubicin delayed death in some patients.
We conclude that patients with breast cancer and liver metastases who have abnormal biochemistry can usefully be treated with weekly epirubicin 25 mg m-2, adjusting dose intensity according to myelosuppression. This treatment is tolerated well. However, an initial deterioration in liver biochemistry may occur before there is a response to epirubicin.
